This Week in Anesthesiology — Oct 12, 2026

This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice.

Welcome to This Week in Anesthesiology. This week we're covering 10 notable papers spanning the older and frail surgical patient, perioperative analgesia and chronic pain, and blood, transfusion and population-level epidemiology. Let's dive in.

We start with the older patient, where three papers ask how much preoperative assessment and preparation actually change what happens in the operating room. In the Journal of Clinical Anesthesia, Wang and colleagues randomized one hundred adults aged 65 or older with elevated frailty risk, all having elective gastrointestinal surgery, to either usual care or volume optimization before induction [1]. The optimization was guided by passive leg raising and echocardiographic velocity-time integral, and nearly every patient in that arm turned out to be fluid responsive and received gelatin boluses. Any mean arterial pressure below 65 in the first fifteen minutes after induction fell from about seven in ten patients to under four in ten, meaning roughly one patient in three was spared an early hypotensive reading. The authors are notably candid, though: the difference in the lowest pressure was only about 4 millimetres of mercury, the overall burden of hypotension was modest, and whether any of this translates into clinical benefit remains uncertain. It is a single-centre trial with a surrogate endpoint, so it strengthens the physiological case without yet establishing an outcome benefit. Also in the Journal of Clinical Anesthesia, Tan and colleagues pooled 677 surgical patients aged 65 and over from two cohort studies and asked which of the five FRAIL scale questions carried the most prognostic weight [2]. Difficulty climbing one flight of stairs was the strongest signal, associated with roughly two and a half times the odds of non-home discharge and about a fifth longer hospital stay, while difficulty walking one block roughly tripled the odds of non-home discharge. The authors suggest these two yes or no questions could serve as a rapid screen, though this is a post-hoc analysis and has not been tested as a decision tool. Finally, in Anesthesia and Analgesia, Tesaki and colleagues used a clever natural experiment: a hospital policy of routine echocardiography for everyone aged 75 and over [3]. Comparing patients just above and just below that cutoff, a regression discontinuity design, they found no clear evidence that age-based echocardiography reduced intraoperative hypotension or improved mortality, kidney injury, or length of stay. The point estimates leaned toward benefit but were imprecise, so meaningful benefit or harm cannot be excluded. Taken together, these papers suggest that targeted, physiology-driven or function-driven assessment may carry more information than age alone, but none yet links a specific preoperative strategy to hard outcomes.

Our second theme is analgesia, from the intraoperative choice of muscle relaxation to system-wide opioid stewardship. The paper with the most immediate intraoperative relevance comes from Anesthesia and Analgesia, where Wang and colleagues randomized 180 patients undergoing posterior lumbar interbody fusion to deep or moderate neuromuscular blockade [4]. Chronic postsurgical pain at three months fell from about a third of patients with moderate block to about a fifth with deep block, roughly a forty percent relative reduction. The deep block group also had lower early pain scores, less opioid use, and higher surgeon satisfaction. Mechanistically, muscle injury markers were lower on the first postoperative day, and six-month MRI showed better preserved paraspinal muscle area and less fatty infiltration, supporting the idea that reduced retraction injury is the pathway. The important caveat is that by six months the difference in chronic pain was no longer statistically significant, so the trial shows a clear early benefit but not a durable one, from a single trial. In the Journal of Clinical Anesthesia, Shariat and colleagues randomized 271 cardiac surgery patients having sternotomy to standard multimodal care, an erector spinae plane block, or a superficial parasternal intercostal plane block [5]. Here the primary hypothesis of reduced opioid consumption was largely not borne out: there was no significant difference in opioid use intraoperatively or on postoperative days zero through two, with only a marginal difference on day three driven by the erector spinae group. Maximum pain scores, however, were consistently lower in both block groups through day three. So these fascial plane blocks appear to improve reported pain without clearly sparing opioids, and the trial does not settle which block, if either, is preferable. Zooming out to the institutional level, Whalen and colleagues, again in Anesthesia and Analgesia, examined nearly fifty thousand patients across a decade before and after an enhanced surgical recovery framework was rolled out across multiple specialties [6]. Use of multimodal analgesia rose in every discharge group, and among patients staying two or more days, outpatient opioid prescribing at thirty days was cut roughly in half, while maximum pain scores stayed stable. Interestingly, opioid use began falling during the planning phase, before protocols launched, hinting at a culture effect. As a retrospective before-and-after study, it cannot exclude secular trends, but it adds real-world support that structured programmes can lower opioid exposure without worse pain.

Our third theme covers blood, transfusion, and what large datasets reveal about the populations we anaesthetise. In Anesthesia and Analgesia, Snegovskikh and colleagues described anaemia in over 280 thousand adults undergoing more than 420 thousand procedures at one tertiary centre [7]. Just under three in ten patients were anaemic before surgery by World Health Organization criteria, and that figure climbed to about half of women when a gender-neutral threshold was applied. Among previously non-anaemic patients admitted after surgery, about three quarters of those patients developed new anaemia, and recovery was slow, with roughly three in ten of these newly anaemic patients still anaemic a year later. Black patients, older adults, and women carried a disproportionate burden. This is descriptive data, but it frames postoperative anaemia as a long tail problem extending well beyond discharge, and the authors see it as an opportunity for patient blood management programmes. On the transfusion side, the Journal of Clinical Anesthesia published TOP-CLOT, from Cushing and colleagues, the first clinical trial of pathogen-reduced cryoprecipitate, which can be stored thawed at room temperature for up to five days [8]. Bleeding cardiac surgery patients were cluster-randomized by month to this product or conventional cryoprecipitate. The pathogen-reduced product reached the patient about twenty minutes faster, but total blood components transfused over thirty days were identical, and the trial was stopped early for futility after enrolling about a third of its planned sample. The authors emphasise that equivalence cannot be concluded; faster availability did not translate into fewer transfusions here.

Two papers from the British Journal of Anaesthesia round out the week with population-level views. Weiniger and colleagues prospectively captured nearly ten thousand Caesarean deliveries across 361 centres in 31 European countries [9]. General anaesthesia was used in about one in seven deliveries overall, rising to just over half of emergency cases, roughly five times the rate in elective cases. Strikingly, in elective cases where general anaesthesia was the first choice, maternal request was the most common reason, and conversion from neuraxial to general anaesthesia occurred in about one in sixteen elective cases. The authors stress that the data cannot explain these differences, but they offer a contemporary European benchmark. And in a genetic epidemiology study, Aboelsaod and colleagues combined four decades of United Kingdom malignant hyperthermia data with UK Biobank genotypes [10]. They estimate the prevalence of clinical susceptibility at roughly one in 39 thousand, far rarer than the prevalence of the associated RYR1 variants. Index cases had about a 46 percent chance of reacting with each anaesthetic, risk varied up to 125-fold across recurrent RYR1 variants, and the declining incidence over time did not fit simple autosomal dominant inheritance. The authors propose a threshold inheritance model instead, which, if confirmed, would have implications for how genotyping and contracture testing are interpreted.

If you only have time for one paper this week, make it the deep versus moderate neuromuscular blockade trial in lumbar fusion from Anesthesia and Analgesia [4]. It links a routine intraoperative choice to chronic pain through a plausible, imaged mechanism, while leaving open whether the benefit persists beyond three months.

Here is what this week's evidence adds up to in Anesthesiology. First, deep neuromuscular blockade in lumbar fusion reduced three-month chronic pain and early opioid use in a single randomized trial, but the six-month difference was not significant, so durability and generalisability remain unsettled. Second, in older and frail patients, preinduction fluid optimization reduced early hypotensive readings, two simple mobility questions flagged higher-risk patients, and age-triggered echocardiography showed no clear benefit; together this favours targeted over age-based assessment, though none of it yet demonstrates improved hard outcomes. Third, fascial plane blocks for sternotomy lowered pain scores without clearly reducing opioids, while an institution-wide recovery programme was associated with substantially less opioid prescribing, from observational data. Fourth, faster-available pathogen-reduced cryoprecipitate did not reduce transfusions in an underpowered trial, and postoperative anaemia emerges as common and persistent, pointing to post-discharge blood management as an open question. Finally, malignant hyperthermia risk appears to follow a threshold rather than simple dominant inheritance, a model that still needs confirmation.

That's your roundup for This Week in Anesthesiology. The full transcript and references are available on the episode page. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And a quick rating on Apple Podcasts or Spotify helps other physicians discover the show.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.